|
Market Closed -
Nasdaq
23:00:00 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 2.570 USD | -4.81% |
|
-7.22% | +80.99% |
| 10-15 | Edesa Biotech, Inc. Receives FDA IND Clearance For Phase 2 Clinical Study Of EB06 In Vitiligo | CI |
| 08-20 | Edesa Biotech Launches Public Offering of Common Shares, Warrants | MT |
| Market Cap | 34.72M 31.1M 28.61M 25.92M 48.45M 3.3B 49.36M 341M 137M 1.73B 130M 128M 5.47B | P/E 2026 * |
-1.29x | P/E 2027 * | -1.24x |
|---|---|---|---|---|---|
| Enterprise Value | 34.72M 31.1M 28.61M 25.92M 48.45M 3.3B 49.36M 341M 137M 1.73B 130M 128M 5.47B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
86.45% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| EDSA | Delayed | |
CBOE
| EDSA | Real-time |
| 1 day | -4.81% | ||
| 1 week | -7.22% | ||
| 1 month | -38.95% | ||
| 3 months | -49.71% | ||
| 6 months | -85.94% | ||
| Current year | +80.99% |
| 1 week | 2.46 |  | 2.86 |
| 1 month | 2.46 | | 4.22 |
| Current year | 0.72 | | 20.32 |
| 1 year | 0.72 | | 20.32 |
| 3 years | 0.72 | | 20.32 |
| 5 years | 0.72 | | 62.65 |
| 10 years | 0.72 | | 133.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pardeep Nijhawan
CEO | Chief Executive Officer | 55 | 01/08/2015 |
Peter Weiler
DFI | Director of Finance/CFO | 57 | 01/05/2025 |
Michael Brooks
PSD | President | 48 | 07/06/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Sean MacDonald
CHM | Chairman | 50 | 07/06/2019 |
Pardeep Nijhawan
BRD | Director/Board Member | 55 | 07/06/2019 |
Carlo Sistilli
CHM | Chairman | 70 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/5/26 A | Free | Founder | 6,893 | 0.0510% | ||
| 9/1/26 A | Free | Founder | 5,714 | 0.0593% | ||
| 8/3/26 A | Free | Founder | 5,324 | 0.0553% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.81% | -7.22% | +38.17% | -20.19% | 34.72M | |
| -0.62% | -1.87% | +42.87% | +64.15% | 63.77B | |
| +0.35% | +3.20% | +14.40% | +81.76% | 56.37B | |
| +0.53% | +1.96% | +15.37% | +106.81% | 54.62B | |
| -2.81% | -4.31% | +23.50% | +47.83% | 44.06B | |
| -0.33% | -1.93% | +19.28% | +98.80% | 42.11B | |
| +0.55% | +2.31% | +225.14% | +866.21% | 41B | |
| +3.27% | +47.96% | +112.67% | +96.48% | 34.92B | |
| +1.22% | -1.44% | +14.89% | +47.15% | 32.82B | |
| +0.89% | +20.55% | -40.62% | +349.24% | 24.7B | |
| Average | -0.18% | +6.09% | +46.57% | +173.83% | 39.44B | |
| Weighted average by Cap. | +0.18% | +5.48% | +47.88% | +177.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -17.52M -15.69M -14.44M -13.08M -24.45M -1.66B -24.91M -172M -69.11M -875M -65.77M -64.37M -2.76B | -23.88M -21.39M -19.67M -17.82M -33.32M -2.27B -33.94M -235M -94.17M -1.19B -89.61M -87.71M -3.76B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | $2.570 | -4.81% | 30,635 |
| 29/10/26 | $2.700 | +5.47% | 44,349 |
| 28/10/26 | $2.560 | -2.66% | 70,685 |
| 27/10/26 | $2.630 | +1.54% | 25,869 |
| 26/10/26 | $2.590 | -6.50% | 63,894 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EDSA Stock
Select your edition
All financial news and data tailored to specific country editions
